Nation sees therapeutics success
admin
2023-01-28 12:13:16
0

Pharmacists check prescription information at a fever clinic in Minhang district of Shanghai on Jan 8. The small molecule drugs to treat COVID-19 had been put into use in community health centers in Shanghai to better play their roles in "early detection, early intervention and early diversion". WANG XIANG/XINHUA

Domestically developed COVID-19 drug therapies lower risk of hospitalization

China will create broad-spectrum treatments to tackle mutated strains of the COVID-19 virus and develop drugs with novel mechanisms to fight the pathogen, according to a document provided to China Daily.

As of Jan 19, a total of 10 domestically made COVID-19 drugs had either been granted official or conditional market approval or were authorized to treat symptoms of the pathogen, the document stated.

The document was issued by the specialized team for COVID-19 medicine research and development under the Joint Prevention and Control Mechanism of the State Council, China's Cabinet.

China also had 23 drugs on the key COVID-19 medicine list that were in active development or undergoing real-world evidence studies after receiving market approval, it said.

"The team will continue to facilitate the development of safe and effective treatments that can cover the whole course of the disease and are suitable for all populations," it added.

Since the COVID-19 pandemic began, China's novel coronavirus drug development process has followed three broad technical paths- stopping the virus from entering cells, inhibiting viral replication in the body and regulating the body's immune system.

In December 2021, China granted official market approval to its first homegrown neutralizing monoclonal neutralizing antibody cocktails - BRII-196 and BRII-198. It is a combination therapy administered through intravenous infusion that can lower the risk of hospitalization and death by nearly 80 percent, according to its phase-three clinical trial results.

Meanwhile, Chinese scientists have been developing small-molecule oral treatments for COVID-19.A breakthrough came in July when China granted conditional authorization for the oral antiviral Azvudine to treat COVID-19. The drug was originally used to treat HIV.

This year, China will accelerate the development of small-molecule oral drugs. In mid-January, the National Medical Products Administration received applications for market approval for new antivirals SIM0417 and VV116. Another antiviral called RAY1216 had recently finished recruiting for its late-stage clinical trials.

Besides finding treatments for COVID-19, Chinese scientists are researching new drugs to prevent infections or regulate the body's immune system, with a handful of candidates currently in phase two or three clinical trials. Some notable examples include the targeted inhibitor drug TDI01 and HY3000 peptide nasal spray.

zhangzhihao@chinadaily.com.cn

相关内容

热门资讯

银河磁体涨2.07%,成交额1... 7月2日,银河磁体盘中上涨2.07%,截至09:44,报29.14元/股,成交1.27亿元,换手率1...
墨尔本一托儿所员工涉性侵幼童,... 转自:三湘都市报澳大利亚墨尔本一名托儿所26岁男性工作人员,被控性侵8名年龄介于5个月至2岁的婴幼儿...
上万名也门民众声援加沙并庆祝以... 转自:央视近日,上万名也门民众来到首都萨那南部的七十广场,举行声援加沙地带的每周例行集会。此次集会除...
马里多地遇袭,军方打死80多名... 转自:上观新闻新华社达喀尔7月1日电(记者司源)巴马科消息:马里军方1日发表声明说,马里中部和西部多...
上海楼市“半年报”:一二手房成... 格隆汇7月2日|据上观,今年以来,上海持续落实好“沪九条”“沪七条”等各项政策措施,房地产市场总体延...
正帆科技跌2.12%,成交额5... 7月2日,正帆科技盘中下跌2.12%,截至09:46,报35.14元/股,成交5486.31万元,换...
港股高开 长春高新拟赴港股上市 每经记者|曾子建    每经编辑|叶峰     7月2日早盘,港股市场高开后震荡上...
ETF融资榜 | 光伏ETF(...        2025年7月1日,光伏ETF(515790.SH)收跌0.45%,成交6.15亿元。...
豪能股份跌2.06%,成交额4... 7月2日,豪能股份(维权)盘中下跌2.06%,截至09:46,报14.76元/股,成交4551.58...
润禾材料跌2.22%,成交额2... 7月2日,润禾材料盘中下跌2.22%,截至09:47,报25.60元/股,成交2030.65万元,换...